Biocon Biologics Expands Global Rights to Adalimumab Biosimilar Hulio

Biocon Biologics, a company based in Bengaluru, India, has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB).

This new deal gives Biocon Biologics full control over the manufacturing, development, and selling of a medicine called Hulio.

Hulio is a version of another medicine called adalimumab.

Before this, FKB made the medicine, and Biocon Biologics sold it.

Now, Biocon Biologics will handle everything.

They will start making the medicine in their own facilities after getting the necessary approvals.

FKB will still help with some development costs and get paid some fees.

This move helps Biocon Biologics make the medicine more affordable and available to people who need it worldwide.

The company's stock price has also gone up recently.